Effect of oral administration of prostaglandin E1 on erectile dysfunction

British Journal of Urology

Volumn 80, Issue 5, 1997, Pages 772-775

  Sato, Y ^a   Horita, H ^a,b   Adachi, H ^a,b   Suzuki, N ^a,b   Tanda, H ^a,b   Kumamoto, Y ^a,b   Tsukamoto, T ^a,b  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Sanjukai Hospital

Author keywords

Erectile dysfunction; Limaprost; Nocturnal penile tumescence; Oral PGE1 agent; Penile rigidity

Indexed keywords

GOSYA JINKI GAN; LIMAPROST; PROSTAGLANDIN E1; UNCLASSIFIED DRUG;

ARTICLE; CHINESE HERB; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FLUSHING; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PENIS DISEASE; PENIS ERECTION; PENIS NOCTURNAL TUMESCENCE; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUAL FUNCTION; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGED; ALPROSTADIL; COITUS; DRUGS, CHINESE HERBAL; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0031400329     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kim ED, McVary KT. Topical prostaglandin-E1 for the treatment of erectile dysfunction. J Urol 1995; 153: 1828-30
2. Wolfson B, Pickett S, Scott NE, deKernion JB, Rajfer J. Intraurethral prostaglandin E-2 cream: a possible alternative treatment for erectile dysfunction. Urology 1993; 42: 73-5
3. Padma-Nathan H, Keller T, Proppiti R, Lue TF, Tam P, Place V. Hemodynamic effects of intraurethral aloprostadil: the mediated urethral system for erection. Int J Imp Res 1994; 6 (suppl 1): A42
4. Boolell M, Allen MJ, Ballard SA et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for treatment of penile erectile dysfunction. Int J Imp Res 1996; 8: 47-52
5. Gloub M, Zia P, Matsuno M, Horton R. Metabolism of prostaglandins A1 and E1 in men. J Clin Invest 1975; 56: 1404-10
6. Tsuboi T, Fujitani B, Maeda K et al. Effect of OP-1206, a prostaglandin E1 derivative, on guinea-pig platelet functions. Thromb Res 1980; 20: 573-80
7. Tsuboi T, Hatano K, Nakatuji B. Pharmacological evaluation of OP 1206, a prostaglandin E1 derivative, as an antianginal agent. Arch Int Pharmacodyn Ther 1980; 247: 89-102
8. Ohno H, Morikawa Y, Hirata F. Studies on 15-hydroxyprostaglandin dehydrogenase with various prostaglandin analogues. J Biochem 1978; 84: 1485-90
9. Murai C, Sasaki T, Osaki H, Hatakeyama A, Shibata S, Yoshinaga K. Oral limaprost for Raynaud's phenomenon. Lancet 1989; 2: 1218
10. Takeuchi A, Hashimoto T. Oral prostaglandin E1 as a therapeutic modality for leg ulcers in Behçet's disease. Int J Clin Pharm Res 1987; 7: 283-9
11. Saito Y, Kitani Y, Fujita T. Thermographic evaluation of the effects of PGE1 derivative, OP-1206 α-CD. Biomed Thermography 1987; 7: 137-9
12. Sato Y, Kumamoto Y, Suzuki N et al. Oral administration of prostaglandin E1 for the treatment of erectile dysfunction. Impotence 1991; 6: 349-55
13. Terasawa K. Kampo - Japanese Oriental Medicine, Insight from Clinical Cases. Tokyo: Standard Mcintyre, 1993: 75-7
14. Yamaguchi Y, Kumamoto Y. Study of sexual function of male diabetics. Jpn J Urol 1994; 85: 1327-35
15. Suzuki N, Kumamoto Y. Study of sexual function in male hemodialysis patients. Jpn J Urol 1995; 86: 1088-97
16. Kumamoto Y, Yamaguchi Y, Sato Y et al. Effects of antiandrogens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate. Acta Urol Jpn 1990; 36: 227-44
17. Mouri K, Kumamoto Y, Ohno K, Aoki M. Evaluation of erectometer as a new diagnostic method for impotence. Jpn J Urol 1985; 76: 1478-85
18. Ohyama T, Maekawa M. The effect of hachimijiougan on impotent patients. Acta Urol Jpn 1982; 28: 493-7
19. Nishizawa Y. The effect of hachimijiougan on patients with impotence. Acta Urol Jpn 1983; 29: 547-58
20. Tong YC, Hung YC, Lin SN, Cheng JT. Effect of 'Ryu-Wei-Ti-Huang-Wan' on the sexual activity of diabetic rats. Impotence 1995; 10: 87 (Abstract)
21. Takayama H, Konishi T, Kounami T et al. Clinical effects of Gosyajinki-gan for male infertility. Acta Urol Jpn 1984; 30: 1685-9
22. Sidi AA, Reddy P, Chen K. Patients acceptance of and satisfaction with vasoactive intracavernous pharmacotherapy for impotence. J Urol 1988; 140: 293-4
23. Christ JG. Penis as a vascular organ. Urol Clin North Am 1995; 22: 727-45
24. Allen RP, Engel RM, Smolev JK, Brendler CB. Comparison of duplex ultrasonography and nocturnal penile tumescence in evaluation of impotence. J Urol 1994; 151: 1525-9
25. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802-15
26. Lumley P, Humphrey PP, Kennedy J, Coleman RA. Comparison of potencies of some prostaglandins as vasodilators in three vascular beds of the anaesthetized dog. Eur J Pharmacol 1982; 81: 421-30
27. Kim N, Vardi Y, Padma-Nathan H, Daley J, Saenz de Tejada I. Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest 1993; 91: 437-42
28. Moreland RB, Trash A, McMillin MA, Smith B, Goldstein I, Saenz de Tejada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-β1 in human corpus cavernosum smooth muscle. J Urol 1995; 153: 826-34